Lexicon Pharmaceuticals (LXRX) Cash from Operations: 2009-2024
Historic Cash from Operations for Lexicon Pharmaceuticals (LXRX) over the last 16 years, with Dec 2024 value amounting to -$178.8 million.
- Lexicon Pharmaceuticals' Cash from Operations rose 9.15% to -$20.4 million in Q4 2012 from the same period last year, while for Dec 2012 it was -$94.5 million, marking a year-over-year decrease of 7.42%. This contributed to the annual value of -$178.8 million for FY2024, which is 10.43% down from last year.
- As of FY2024, Lexicon Pharmaceuticals' Cash from Operations stood at -$178.8 million, which was down 10.43% from -$161.9 million recorded in FY2023.
- In the past 5 years, Lexicon Pharmaceuticals' Cash from Operations registered a high of -$87.0 million during FY2021, and its lowest value of -$178.8 million during FY2024.
- Its 3-year average for Cash from Operations is -$143.2 million, with a median of -$161.9 million in 2023.
- In the last 5 years, Lexicon Pharmaceuticals' Cash from Operations slumped by 225.62% in 2020 and then soared by 39.14% in 2021.
- Over the past 5 years, Lexicon Pharmaceuticals' Cash from Operations (Yearly) stood at -$143.0 million in 2020, then surged by 39.14% to -$87.0 million in 2021, then fell by 2.11% to -$88.9 million in 2022, then plummeted by 82.21% to -$161.9 million in 2023, then dropped by 10.43% to -$178.8 million in 2024.